

RESULTS OF EXTRAORDINARY GENERAL MEETING

Rhythm Biosciences Ltd (ASX: RHY) (“**Rhythm**” or the “**Company**”) advises an Extraordinary General Meeting of the Company was held today, Monday 31 March 2025, commencing at 10:00 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolution put to shareholders and proxies received in respect of the resolution are set out in the attached proxy summary.

All resolutions were successfully passed at the EGM by way of a poll.

The Board thanks shareholders for their ongoing support.

- ENDS -

Authorised for release by the Board.

For further information contact us via investors@rhythmbio.com:

Mr. Otto Buttula Non- Executive Chairman	Mr. Mark Licciardo Company Secretary
--	--

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform’s multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

E investors@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director

Disclosure of Proxy Votes

Rhythm Biosciences Limited

Extraordinary General Meeting

Monday, 31 March 2025



GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 CHANGE OF AUDITOR	P	80,093,825	79,400,513 99.13%	9,417 0.01%	253,583	683,895 0.85%	80,237,231 99.99%	9,417 0.01%	253,583	Carried
2 APPROVAL OF ISSUE OF PLACEMENT OPTIONS	P	61,644,477	60,186,029 97.63%	774,553 1.26%	28,246	683,895 1.11%	60,928,424 98.59%	868,876 1.41%	28,246	Carried
3 APPROVAL OF ISSUE OF ADVISOR OPTIONS	P	76,636,372	75,177,924 98.10%	774,607 1.01%	49,566	683,841 0.89%	75,920,265 98.87%	868,930 1.13%	49,566	Carried
4 RATIFICATION OF PRIOR ISSUE OF SHARES	P	61,637,909	60,151,204 97.59%	802,864 1.30%	34,814	683,841 1.11%	60,893,545 98.70%	802,864 1.30%	129,137	Carried

